Text Size

Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis

This study has been completed.
Sponsor:
Information provided by:
Regional Hospital Holstebro
ClinicalTrials.gov Identifier:
NCT00345137
First received: June 24, 2006
Last updated: NA
Last verified: June 2006
History: No changes posted
  Purpose

The study tests the hypothesis that systemic and renal nitric oxide availability is changed in polycystic kidney disease and chronic glomerulonephritis.


Condition Intervention Phase
ADPKD
Glomerulonephritis
 Drug: Ng-monomethyl-L-arginine (drug)
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind
Official Title: Phase 1 Study of Systemic Effects of Ng-Monomethyl-L-Arginine on Renal Hemodynamics in Patients With Polycystic Kidney Disease and Chronic Glomerulonephritis

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Regional Hospital Holstebro:

Estimated Enrollment: 75
Detailed Description:

In a randomized, placebo controlled design, the effects of systemic treatment with monomethyl-L-arginine are studied on:

  1. renal hemodynamics
  2. renal sodium excretion and lithium clearance
  3. blood pressure and heart rate
  4. plasma levels of vasoactive hormones

in patients with adult polycystic kidney disease and chronic glomerulonephrits. The results are compared with a group of healthy control subjects

  Eligibility

Ages Eligible for Study:   20 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Healthy controls

  • Age 20 to 60 years
  • Both men and women
  • Weight below 100 kg
  • Normal clinical examination and laboratory screening
  • Fertile women only if using contraception
  • Informed consent according to the regulations of the local etics committee

Chronic glomerulonephritis

  • Biopsy veryfied chronic glomerulonephritis
  • P-creatinine < 250 µmol/L
  • Weight below 100 kg
  • Age 20 to 60 years
  • Both men and women
  • Informed consent according to the regulations of the local etics committee

Adult polycystic kidney disease (APKD)

  • Diagnosis of APKD by family history and renal ultrasound or renal angiography
  • P-creatinine < 250 µmol/L
  • Weight below 100 kg
  • Age 20 to 60 years
  • Both men and women
  • Informed consent according to the regulations of the local etics committee

Exclusion Criteria:

Healthy controls

  • History or clinical evidence of diseases of the heart and blood vessels, kidneys, liver and pancreas, endocrine organs, lungs, neoplastic disease, myocardial infarction or cerebrovascular insult as evaluated by clinical examination and laboratory screening
  • Current medication
  • Drugs or alcohol abuse
  • Pregnancy
  • Previously within one year received more than 0.2 mSV radioactive treatment or diagnostic substances
  • Donation of blood less than 1 month before the experiments

Chronic glomerulonephritis

  • Apart from chronic glomerulonephritis and hypertension no history of diseases of the heart and blood vessels, liver and pancreas, endocrine organs, lungs, myocardial infarction, cerebrovascular insult or neoplastic disease.
  • Patients with nephrotic syndrome or secondary glomerulonephritis
  • Current medication other than antihypertensive therapy
  • Drugs or alcohol abuse
  • Pregnancy
  • Previously within one year received more than 0.2 mSV radioactive treatment or diagnostic substances

Adult polycystic kidney disease

  • Apart from APKD and hypertension no history of diseases of the heart and blood vessels, liver and pancreas, endocrine organs, lungs, myocardial infarction, cerebrovascular insult or neoplastic disease.
  • Current medication other than antihypertensive therapy
  • Drugs or alcohol abuse
  • Pregnancy
  • Previously within one year received more than 0.2 mSV radioactive treatment or diagnostic substances
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00345137

Sponsors and Collaborators
Regional Hospital Holstebro
Investigators
Study Chair: Erling B Pedersen, Professor Dept. of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark
Principal Investigator: Jesper N Bech, MD, Ph.d. Dept. of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00345137     History of Changes
Other Study ID Numbers: MED.RES.HOS.1995.02.JNB
Study First Received: June 24, 2006
Last Updated: June 24, 2006
Health Authority: Denmark: National Board of Health

Keywords provided by Regional Hospital Holstebro:
Renal hemodynamics
Nitric oxide

Additional relevant MeSH terms:
Glomerulonephritis
Kidney Diseases
Polycystic Kidney Diseases
Polycystic Kidney, Autosomal Dominant
Chronic Disease
Nephritis
Urologic Diseases
 Kidney Diseases, Cystic
Disease Attributes
Pathologic Processes
Omega-N-Methylarginine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 13, 2013